QuickBird Medical
  • Case Studies
    • Case Studies
    • Customers
  • Services
    • Development: DiGA
    • Development: Medical Software – EU & MDR
    • Development: Medical Software – US & FDA
    • Development: Health Apps
    • Development: Wearables for Medical Devices
    • Development: Decision Support Systems
    • Development: Medical AI Systems
    • Legal Manufacturer for Medical Devices
    • BSI TR-03161 for DiGA
    • ePA & Health ID for DiGA
    • Further Services
  • Insights
  • Team
  • Jobs
  • Contact
  • German
Select Page
DiGA: Guidelines for demonstrating positive supply effects

DiGA: Guidelines for demonstrating positive supply effects

by Alexander Fenkiw | Nov 25, 2025 | diga-whitepaper, Unkategorisiert

 What is the point of a DiGA if it does not improve patients’ lives? There is none! This is why DiGAs are only justified when their positive supply effect has been proven. Only then do you have a chance of being permanently included in the BfArM register....
MDR Risk Class I vs. IIa: Differences for software medical devices

MDR Risk Class I vs. IIa: Differences for software medical devices

by Alexander Fenkiw | Jan 9, 2025 | medical-software-whitepaper

At the beginning of the development of a software medical device, the central question is: Which risk class applies to my product? Risk classification has serious implications and significantly influences the cost and time frame of product development. In extreme...
Phrasing of the intended purpose for (software) medical devices

Phrasing of the intended purpose for (software) medical devices

by Alexander Fenkiw | Sep 10, 2024 | medical-software-whitepaper

How do I actually decide whether my product is a medical device? Where do I start when I want to determine its risk class? And what statements can I use to promote my product in the end? The answers to these and many other questions can be answered on the basis of...
Validation of medical device software according to MDR

Validation of medical device software according to MDR

by Alexander Fenkiw | Dec 30, 2022 | medical-software-whitepaper, Unkategorisiert

If you are developing software that qualifies as a medical device under the Medical Device Regulation (MDR), validation is one of the most critical issues. Successful validation of your software is an absolute prerequisite for bringing your medical device to market....
Guide to §374a SGB V – Interoperability for DiGA, aids & implants

Guide to §374a SGB V – Interoperability for DiGA, aids & implants

by Alexander Fenkiw | May 3, 2022 | diga-whitepaper

Attention manufacturers of electronic aids, implants and DiGA! From mid-2024, a new legal requirement will apply to improve interoperability between medical devices and digital health applications (DiGA) approved by the BfArM: §374a SGB V Specifically, this involves...
« Older Entries
Next Entries »

Insider-Empfehlungen für DiGA-Hersteller in 2026
Downloaden Sie jetzt unser Whitepaper

Insider-Empfehlungen für Software-Medizinprodukt-Hersteller in 2026
Downloaden Sie jetzt unser Whitepaper


Sie planen eine Medical Software oder DiGA?

Sprechen Sie mit unserem Geschäftsführer Malte Bucksch

+49 (0) 89 54998380
kontakt@quickbirdmedical.com

Are you planning to develop medical software or a digital health application?

Speak with our managing director, Malte Bucksch

+49 (0) 89 54998380
contact@quickbirdmedical.com
Kontakt

+49 (0) 89 54998380
kontakt@quickbirdmedical.com

 

Whitepaper

13 wichtige Empfehlungen für angehende DiGA-Hersteller 2026

13 wichtige Empfehlungen für angehende Medizinprodukt-Hersteller 2026

Aktuelles

DiGA- und Medical Software-Newsletter

Digital Health Events 2026

Presse – QuickBird in den Medien

© 2026 Impressum | Datenschutz